- Adverse events (AEs) are common in multidrug-resistant tuberculosis (MDR-TB) in both HIV-infected and uninfected patients receiving concurrent antiretroviral therapy (ART)/TB treatment.
- Frequency/severity of AEs are similar between ART-treated vs untreated MDR-TB patients.
Why this matters
- Do not delay concomitant MDR-TB and HIV treatment in patients.
- Educate patients, family members at therapy initiation, actively monitor and treat AEs whenever possible.
- 206 patients (150 HIV+, 56 HIV−); median age, 33 (interquartile range [IQR], 26-41) years.
- 71% HIV+ and 46% HIV− had prior TB treatment.
- 93% HIV+ and 96% HIV− participants experienced >1 clinical or laboratory AE (medians, 8 [IQR, 4-15] and 4 [IQR, 2-9], per participant).
- Most common AEs: peripheral neuropathy (50%), difficulty sleeping (48%), decreased creatinine clearance (46%), hypokalemia (47%).
- HIV+ patients were 2.4 times likelier to experience diarrhea (P=.03).
- 72% (125) HIV+ and 8% (14) HIV− patients had any grade or severe hearing loss, respectively.
- Any grade of colour discrimination loss seen in 9% (17/187) of patients:
- No significant differences in degree/severity seen in HIV+ vs HIV−.
- Prospective, observational study comparing frequency, severity, timing of AEs in MDR-TB/HIV-infected vs MDR-TB/HIV-uninfected South African patients, 2011-2015.
- Funding: NIH.
- Subjectivity bias.
- Novel auditory grading system.
- No follow-up vision testing.